Fibrinogen three-component sealant - PPL Therapeutics

Drug Profile

Fibrinogen three-component sealant - PPL Therapeutics

Alternative Names: Factor I/factor IIa/factor XIII; Fibrinogen/thrombin/factor XIII; Three component fibrin sealant - PPL Therapeutics

Latest Information Update: 20 Apr 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PPL Therapeutics PLC
  • Class Antihaemorrhagics; Blood coagulation factors; Blood proteins; Serine endopeptidases
  • Mechanism of Action Blood coagulation factor replacements; Factor XIII stimulants; Fibrinogen receptor agonists; Fibrinogen replacements; Fibrinogen stimulants; Thrombin replacements; Thrombin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Blood coagulation disorders; Wounds

Most Recent Events

  • 20 Apr 2001 Discontinued - Preclinical for Coagulation disorders in United Kingdom (Topical)
  • 20 Apr 2001 Discontinued - Preclinical for Wounds in United Kingdom (Topical)
  • 21 Nov 2000 Preclinical development for Wounds in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top